A multicenter post-marketing evaluation of the Elixir DESolve® Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study.
Holger NefJens WiebeNiklas F BoederOliver DörrTimm BauerKarl-Eugen HauptmannAzeem LatibAntonio ColomboDieter FischerTanja RudolphNicolas FoinGert RichardtChristian HammPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
Results through 12 months indicate that the DESolve BRS is a safe and effective treatment for coronary lesions, though larger, long-term prospective studies are needed.